Silencing Calumenin Expression via Artificial MicroRNA, a Potential Breakthrough for Inhibiting Proliferation,...

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Calumenin (CALU), a calcium-binding protein, shows variable expression in tumors and is implicated in cancer progression.
• Its specific role in breast cancer (BC) pathogenesis requires further elucidation.

Purpose of the Study:

• To investigate the association between CALU expression and clinicopathological features in breast cancer.
• To functionally assess CALU's role in BC progression using a microRNA-mediated knockdown approach.

Main Methods:

• Quantitative reverse transcription-polymerase chain reaction (q-RT-PCR) to measure CALU expression in BC tissues.
• Correlation analysis between CALU levels and clinicopathological characteristics.
• CALU knockdown in BC cell lines using artificial microRNA (amiR) delivered via episomal vectors.
• Assessment of epithelial to mesenchymal transition (EMT) markers, cell cycle, migration, proliferation, and apoptosis.

Main Results:

• BC tissues exhibited a significant 3.4-fold increase in CALU expression compared to normal tissues.
• CALU expression positively correlated with histological grade, Ki-67, TNM stage, lymph node metastasis, and vascular invasion.
• CALU knockdown led to downregulation of key EMT markers (GSC, MMP2, TIMP1, TGF1, SLUG, ZEB1, ZEB2, SNALI1, TWIST1).
• CALU inhibition resulted in suppressed cell migration and proliferation, cell cycle arrest, and induced apoptosis in BC cell lines.

Conclusions:

• CALU is upregulated in breast cancer and its expression correlates with adverse clinicopathological features.
• CALU knockdown inhibits BC cell progression, supporting its role as a potential promoter of breast cancer.
• Targeting CALU may represent a therapeutic strategy for breast cancer.